surpass cvot tirzepatide SURPASS-CVOT shows delivers comparable cardiovascular safety to dulaglutide in patients with type 2 diabetes and established ASCVD, reinforcing the shift toward therapies that optimize whole cardiometabolic systems. As outcome datasets grow SURPASS-CVOT: Tirzepatide Significantly Reduces Major
Pay in 4 interest-free payments of $5.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2




:max_bytes(150000):strip_icc()/GettyImages-2126120470-4b91f7120b0a450f8c9a674333f424cc.jpg)

















